A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma

Author:

Hussain Maha1,Daignault Stephanie1,Agarwal Neeraj2,Grivas Petros D.1,Siefker-Radtke Arlene O.3,Puzanov Igor4,MacVicar Gary R.5,Levine Ellis Glenn6,Srinivas Sandy7,Twardowski Przemyslaw8,Eisenberger Mario A.9,Quinn David I.10,Vaishampayan Ulka N.11,Yu Evan Y.12,Dawsey Scott1,Day Kathleen C.1,Day Mark L.1,Al-Hawary Mahmoud1,Smith David C.1

Affiliation:

1. University of Michigan; Ann Arbor Michigan

2. Huntsman Cancer Institute; University of Utah; Salt Lake City Utah

3. MD Anderson Cancer Center; University of Texas; Houston Texas

4. Vanderbilt University Medical Center; Nashville Tennessee

5. Division of Hematology and Medical Oncology; Northwestern University Feinberg School of Medicine; Chicago Illinois

6. Roswell Park Cancer Institute; Buffalo New York

7. Stanford Medical Center; Stanford California

8. City of Hope; Duarte California

9. Sidney Kimmel Comprehensive Cancer Center; Johns Hopkins University; Baltimore Maryland

10. Norris Comprehensive Cancer Center; University of Southern California; Los Angeles California

11. Karmanos Cancer Institute; Wayne State University; Detroit Michigan

12. University of Washington and Fred Hutchinson Cancer Research Center; Seattle Washington

Funder

Imclone

National Comprehensive Cancer Network (NCCN)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference61 articles.

1. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;Maase;J Clin Oncol,2005

2. EGFR and cancer prognosis;Nicholson;Eur J Cancer,2001

3. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer;Chow;Anticancer Res,1997

4. Epidermal growth factor-related peptides and their receptors in human malignancies;Salomon;Crit Rev Oncol Hematol,1995

5. Tumor invasion: role of growth factor-induced cell motility;Wells;Adv Cancer Res,2000

Cited by 104 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3